<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s11{background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#1155cc;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s8{border-left: none;background-color:#ffffff;}.ritz .waffle .s0{background-color:#ffffff;text-align:left;font-weight:bold;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s10{background-color:#ffffff;text-align:left;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s4{background-color:#ffffff;text-align:right;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s9{border-left: none;border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s6{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s5{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:middle;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s2{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s7{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}</style><svg style="display:none;" width="16px" height="16px" viewBox="0 0 16 16" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="checked-checkbox-id" d="M17,3 L4.75,3 C3.77875,3 3,3.7875 3,4.75 L3,17 C3,17.9625 3.77875,18.75 4.75,18.75 L17,18.75 C17.97125,18.75 18.75,17.9625 18.75,17 L18.75,4.75 C18.75,3.7875 17.97125,3 17,3 L17,3 Z M9.125,15.25 L4.75,10.875 L5.98375,9.64125 L9.125,12.77375 L15.76625,6.1325 L17,7.375 L9.125,15.25 L9.125,15.25 Z" transform="translate(-3.000000, -3.000000)"></path><path id="unchecked-checkbox-id" d="M17,3.75 L17,16 L4.75,16 L4.75,3.75 L17,3.75 L17,3.75 Z M17,2 L4.75,2 C3.7875,2 3,2.7875 3,3.75 L3,16 C3,16.9625 3.7875,17.75 4.75,17.75 L17,17.75 C17.9625,17.75 18.75,16.9625 18.75,16 L18.75,3.75 C18.75,2.7875 17.9625,2 17,2 L17,2 Z" transform="translate(-3.000000, -2.000000)"></path></defs></svg><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="193199584C0" style="width:551px;" class="column-headers-background">A</th><th id="193199584C1" style="width:100px;" class="column-headers-background">B</th><th id="193199584C2" style="width:100px;" class="column-headers-background">C</th><th id="193199584C3" style="width:100px;" class="column-headers-background">D</th><th id="193199584C4" style="width:100px;" class="column-headers-background">E</th><th id="193199584C5" style="width:257px;" class="column-headers-background">F</th><th id="193199584C6" style="width:100px;" class="column-headers-background">G</th><th id="193199584C7" style="width:100px;" class="column-headers-background">H</th></tr></thead><tbody><tr style="height: 20px"><th id="193199584R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0" dir="ltr">Counselling regarding breech presentation at term &amp; ECV</td><td></td><td></td><td></td><td></td><td class="s1" dir="ltr">Summary Advice:</td><td class="s2" dir="ltr">Context:</td><td class="s2" dir="ltr">Coded:</td></tr><tr style="height: 20px"><th id="193199584R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td class="s3" dir="ltr"></td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s3" dir="ltr">Variables</td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s3" dir="ltr">Parity</td><td class="s4" dir="ltr">Nulliparous</td><td class="s5" dir="ltr"><svg width="16px" height="16px" viewBox="0 0 16 16" style="display:inline;"><use href="#unchecked-checkbox-id" fill="#000000"/></svg></td><td class="s4" dir="ltr">Multiparous</td><td class="s5" dir="ltr"><svg width="16px" height="16px" viewBox="0 0 16 16" style="display:inline;"><use href="#checked-checkbox-id" fill="#000000"/></svg></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s3" dir="ltr">Rh status</td><td class="s4" dir="ltr">Positive</td><td class="s5" dir="ltr"><svg width="16px" height="16px" viewBox="0 0 16 16" style="display:inline;"><use href="#unchecked-checkbox-id" fill="#000000"/></svg></td><td class="s4" dir="ltr">Negative</td><td class="s5" dir="ltr"><svg width="16px" height="16px" viewBox="0 0 16 16" style="display:inline;"><use href="#unchecked-checkbox-id" fill="#000000"/></svg></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s3" dir="ltr">Are there any absolute contraindications to ECV</td><td class="s4" dir="ltr">Yes</td><td class="s5" dir="ltr"><svg width="16px" height="16px" viewBox="0 0 16 16" style="display:inline;"><use href="#unchecked-checkbox-id" fill="#000000"/></svg></td><td class="s4" dir="ltr">No</td><td class="s5" dir="ltr"><svg width="16px" height="16px" viewBox="0 0 16 16" style="display:inline;"><use href="#checked-checkbox-id" fill="#000000"/></svg></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s6"></td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s6"></td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s3" dir="ltr">ECV:</td><td></td><td></td><td></td><td></td><td class="s2">ECV:</td><td></td><td class="s2">ECV:<br></td></tr><tr style="height: 20px"><th id="193199584R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s6" dir="ltr">If no contraindications, advise ECV is appropriate, discuss risks and benefits and implications on mode of delivery</td><td></td><td></td><td></td><td></td><td class="s2 softmerge"><div class="softmerge-inner" style="width:254px;left:-1px">Advise ECV is appropriate, discuss risks and benefits and implications on mode of delivery</div></td><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:97px;left:-1px">If no absolute contraindications to ECV, offer ECV</div></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:598px;left:-1px">Advise ECV is appropriate, discuss risks and benefits and implications on mode of delivery<br></div></td></tr><tr style="height: 20px"><th id="193199584R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s6" dir="ltr">Spontaneous version rates in nulliparous women: 8% after 36 weeks</td><td></td><td></td><td></td><td></td><td class="s2"></td><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:97px;left:-1px">Only include if nulliparous</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s6" dir="ltr">Version rates less than 5% after unsuccessful ECV</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:355px;left:-1px">Version rates less than 5% after unsuccessful ECV</div></td><td class="s8"></td><td class="s9 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Version rates less than 5% after unsuccessful ECV<br></div></td></tr><tr style="height: 20px"><th id="193199584R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s6" dir="ltr">ECV successful in approximately 50% of cases (40% for nulliparous, and 60% for multiparous)</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">ECV successful in approximately 50% of cases (40% for nulliparous, and 60% for multiparous)</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:598px;left:-1px">ECV successful in approximately 50% of cases (40% for nulliparous, and 60% for multiparous)<br></div></td></tr><tr style="height: 20px"><th id="193199584R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s6" dir="ltr">Revert to breech after successful ECV &lt;5%</td><td></td><td></td><td></td><td></td><td class="s2">Revert to breech after successful ECV &lt;5%</td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Revert to breech after successful ECV &lt;5%<br></div></td></tr><tr style="height: 20px"><th id="193199584R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s6" dir="ltr">Tocolysis with beta-sympathomimetics improves success rates</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">Tocolysis with beta-sympathomimetics improves success rates</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Tocolysis with beta-sympathomimetics improves success rates<br></div></td></tr><tr style="height: 20px"><th id="193199584R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s6" dir="ltr">ECV offered from 36 weeks in nulliparous women and from 37 weeks in multiparous women</td><td></td><td></td><td></td><td></td><td class="s2 softmerge"><div class="softmerge-inner" style="width:254px;left:-1px">ECV offered from 36 weeks in nulliparous women and from 37 weeks in multiparous women</div></td><td class="s2 softmerge" dir="ltr"><div class="softmerge-inner" style="width:97px;left:-1px">Contextualise timing of ECV depending on parity</div></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:598px;left:-1px">ECV offered from 36 weeks in nulliparous women and from 37 weeks in multiparous women<br></div></td></tr><tr style="height: 20px"><th id="193199584R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td class="s6" dir="ltr">D-negative women undergoing EVC should have testing for FMH and offered anti-D</td><td></td><td></td><td></td><td></td><td class="s2"></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s6" dir="ltr">Risk of EMCS after ECV is approximately 0.5% (1 in 200)</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:355px;left:-1px">Risk of EMCS after ECV is approximately 0.5% (1 in 200)</div></td><td class="s8"></td><td class="s9 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Risk of EMCS after ECV is approximately 0.5% (1 in 200)<br></div></td></tr><tr style="height: 20px"><th id="193199584R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s6" dir="ltr">Consider regional analgesia / neuraxial blockade for a repeat attempt or for women unable to tolerate ECV without analgesia</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">Consider regional analgesia / neuraxial blockade for a repeat attempt or for women unable to tolerate ECV without analgesia</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:798px;left:-1px">Consider regional analgesia / neuraxial blockade for a repeat attempt or for women unable to tolerate ECV without analgesia<br></div></td></tr><tr style="height: 20px"><th id="193199584R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s3" dir="ltr"></td><td></td><td></td><td></td><td></td><td class="s2"></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s3" dir="ltr">Planned CS:</td><td></td><td></td><td></td><td></td><td class="s2">Planned CS:</td><td></td><td class="s2">Planned CS:<br></td></tr><tr style="height: 20px"><th id="193199584R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s6" dir="ltr">Small reduction in perinatal mortality, balance against other risks and explain it is due to avoidance of prolonged gestation (past 39 weeks) and intrapartum risks (as well as breech birth).</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">Small reduction in perinatal mortality, balance against other risks and explain it is due to avoidance of prolonged gestation (past 39 weeks) and intrapartum risks (as well as breech birth).</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:1098px;left:-1px">Small reduction in perinatal mortality, balance against other risks and explain it is due to avoidance of prolonged gestation (past 39 weeks) and intrapartum risks (as well as breech birth).<br></div></td></tr><tr style="height: 20px"><th id="193199584R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s6" dir="ltr">Increased short term maternal complications</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:355px;left:-1px">Increased short term maternal complications</div></td><td class="s8"></td><td class="s9 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Increased short term maternal complications<br></div></td></tr><tr style="height: 20px"><th id="193199584R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s6" dir="ltr">Increased risk in future pregnancy incl VBAC, ERCS and abnormally invasive placenta</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">Increased risk in future pregnancy incl VBAC, ERCS and abnormally invasive placenta</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">Increased risk in future pregnancy incl VBAC, ERCS and abnormally invasive placenta<br></div></td></tr><tr style="height: 20px"><th id="193199584R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s6" dir="ltr">Increased future risk of stillbirth, though unclear aetiology / association with CS</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">Increased future risk of stillbirth, though unclear aetiology / association with CS</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">Increased future risk of stillbirth, though unclear aetiology / association with CS<br></div></td></tr><tr style="height: 20px"><th id="193199584R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s2" dir="ltr">Planned vaginal breech birth:</td><td></td><td></td><td></td><td></td><td class="s2">Planned vaginal breech birth:</td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Planned vaginal breech birth:<br></div></td></tr><tr style="height: 20px"><th id="193199584R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">27</div></th><td class="s6" dir="ltr">Increases the risk of fetal mortality, low Apgar scores and serious short-term complications, but has not been shown to increase the risk of long-term morbidity</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">Increases the risk of fetal mortality, low Apgar scores and serious short-term complications, but has not been shown to increase the risk of long-term morbidity</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:998px;left:-1px">Increases the risk of fetal mortality, low Apgar scores and serious short-term complications, but has not been shown to increase the risk of long-term morbidity<br></div></td></tr><tr style="height: 20px"><th id="193199584R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">28</div></th><td class="s10" dir="ltr"></td><td></td><td></td><td></td><td></td><td class="s2"></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R28" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">29</div></th><td class="s10" dir="ltr">Individualised assessment of the long-term risks of CS based on their individual risk profile and reproductive intentions</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">Individualised assessment of the long-term risks of CS based on their individual risk profile and reproductive intentions</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:798px;left:-1px">Individualised assessment of the long-term risks of CS based on their individual risk profile and reproductive intentions<br></div></td></tr><tr style="height: 20px"><th id="193199584R29" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">30</div></th><td class="s6" dir="ltr">Maternal complications least with successful vaginal birth, higher for planned CS, highest for EMCS (40% chance of being required).</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">Maternal complications least with successful vaginal birth, higher for planned CS, highest for EMCS (40% chance of being required).</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:798px;left:-1px">Maternal complications least with successful vaginal birth, higher for planned CS, highest for EMCS (40% chance of being required).<br></div></td></tr><tr style="height: 20px"><th id="193199584R30" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">31</div></th><td class="s6" dir="ltr">Perinatal mortality with planned CS = 0.5/1000 vs 2/1000 for vaginal breech vs 1/1000 for vaginal birth.</td><td></td><td></td><td></td><td></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:354px;left:-1px">Perinatal mortality with planned CS = 0.5/1000 vs 2/1000 for vaginal breech vs 1/1000 for vaginal birth.</div></td><td class="s8"></td><td class="s7 softmerge"><div class="softmerge-inner" style="width:1699px;left:-1px">Assess for the following and if any present advise CS as higher risk of failed / complicated birth: hyperextended neck on ultrasound, high estimated fetal weight (more than 3.8 kg), low estimated weight (less than tenth centile), footling presentation, evidence of antenatal fetal compromise.<br></div></td></tr><tr style="height: 20px"><th id="193199584R31" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">32</div></th><td class="s6" dir="ltr"></td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R32" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">33</div></th><td class="s6"></td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R33" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">34</div></th><td class="s3" dir="ltr">Summary Advice:</td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R34" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">35</div></th><td class="s6">Version rates less than 5% after unsuccessful ECV<br>ECV successful in approximately 50% of cases (40% for nulliparous, and 60% for multiparous)<br>Revert to breech after successful ECV &lt;5%<br>Tocolysis with beta-sympathomimetics improves success rates<br>ECV offered from 36 weeks in nulliparous women and from 37 weeks in multiparous women<br>Risk of EMCS after ECV is approximately 0.5% (1 in 200)<br>Consider regional analgesia / neuraxial blockade for a repeat attempt or for women unable to tolerate ECV without analgesia<br>Planned CS:<br>Small reduction in perinatal mortality, balance against other risks and explain it is due to avoidance of prolonged gestation (past 39 weeks) and intrapartum risks (as well as breech birth).<br>Increased short term maternal complications<br>Increased risk in future pregnancy incl VBAC, ERCS and abnormally invasive placenta<br>Increased future risk of stillbirth, though unclear aetiology / association with CS<br>Planned vaginal breech birth:<br>Increases the risk of fetal mortality, low Apgar scores and serious short-term complications, but has not been shown to increase the risk of long-term morbidity<br>Individualised assessment of the long-term risks of CS based on their individual risk profile and reproductive intentions<br>Maternal complications least with successful vaginal birth, higher for planned CS, highest for EMCS (40% chance of being required).<br>Assess for the following and if any present advise CS as higher risk of failed / complicated birth: hyperextended neck on ultrasound, high estimated fetal weight (more than 3.8 kg), low estimated weight (less than tenth centile), footling presentation, evidence of antenatal fetal compromise.<br></td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R35" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">36</div></th><td class="s6"></td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr><tr style="height: 20px"><th id="193199584R36" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">37</div></th><td class="s11" dir="ltr"><a target="_blank" href="#gid=1624945851">Link back to ANC R/V</a></td><td></td><td></td><td></td><td></td><td></td><td></td><td class="s2"></td></tr></tbody></table></div>